Halfdan S.
- Country
- Norway
- Department
- Medical oncology
Research Overview
- Phase III Trial of BI 764532 Plus Carboplatin and Etoposide Versus Carboplatin and Etoposide in Previously Untreated DLL3-Positive Advanced Extrapulmonary Neuroendocrine Carcinoma
- Phase 3 Randomized Trial of Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 14 of 109 partner sites.
Specializations
Oncology Focus
The investigator specializes in colorectal cancer treatment, with particular emphasis on advanced cases exhibiting specific molecular characteristics.
- Metastatic Colorectal Cancer Management
- Molecular Profiling in Cancer Treatment
Their research encompasses innovative therapeutic approaches for patients with microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) tumor profiles.
Immunotherapy Expertise
The investigator focuses on advancing immunotherapeutic approaches in colorectal cancer treatment, particularly exploring combination therapy strategies.
- Novel Immunotherapy Combinations
- Targeted Treatment Protocols
Their work involves evaluating the effectiveness of monotherapy and combination immunotherapy approaches in treating advanced colorectal cancer.
Treatment Innovation
The investigator's work centers on developing comparative treatment strategies for colorectal cancer patients, including both traditional and innovative therapeutic approaches.
- Treatment Response Assessment
- Progressive Disease Management
Their expertise includes evaluating various therapeutic interventions for metastatic colorectal cancer patients with specific genetic profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.